Gilead Sciences, Inc.

GILD
NASDAQ
Company profile


Market capMega (84.58B)
Company CEODaniel O'Day

Gilead Sciences, Inc.

GILD
NASDAQ
Company profile


Market capMega (84.58B)
Company CEODaniel O'Day
$66.85Price snapshot
$2.52Annual dividend
3.77 %Dividend yield
10.91%Dividend growth (3y)
N/ATraling P/E
-Forward P/E
-Payout ratio
-EPS

GILD DIVIDEND PAYOUT HISTORY

Loading...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.

The company was founded by Michael L.

PRICE HISTORY Gilead Sciences, Inc.

Loading price stock history...

Gilead Sciences, Inc. latest news

Loading latest news...